481.67
price up icon0.12%   0.60
after-market After Hours: 485.99 4.32 +0.90%
loading
Alnylam Pharmaceuticals Inc stock is traded at $481.67, with a volume of 1.03M. It is up +0.12% in the last 24 hours and up +6.63% over the past month. Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$481.07
Open:
$481.65
24h Volume:
1.03M
Relative Volume:
0.88
Market Cap:
$63.14B
Revenue:
$2.46B
Net Income/Loss:
$-319.09M
P/E Ratio:
-195.25
EPS:
-2.4669
Net Cash Flow:
$-52.09M
1W Performance:
+4.61%
1M Performance:
+6.63%
6M Performance:
+105.35%
1Y Performance:
+62.32%
1-Day Range:
Value
$476.44
$492.62
1-Week Range:
Value
$453.82
$492.62
52-Week Range:
Value
$205.87
$492.62

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Name
Alnylam Pharmaceuticals Inc
Name
Phone
(617) 551-8200
Name
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Employee
2,230
Name
Twitter
@alnylam
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
ALNY's Discussions on Twitter

Compare ALNY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
481.67 63.06B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
416.81 104.76B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
578.05 60.32B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ARGX
Argen X Se Adr
843.66 51.55B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
165.76 34.49B 398.11M -1.03B -868.57M -5.7032

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-04-25 Upgrade Oppenheimer Perform → Outperform
Aug-04-25 Upgrade Wolfe Research Underperform → Peer Perform
Jul-30-25 Resumed Raymond James Outperform
Jul-21-25 Initiated Truist Buy
Mar-31-25 Initiated Redburn Atlantic Buy
Mar-24-25 Upgrade JP Morgan Neutral → Overweight
Nov-12-24 Downgrade Wolfe Research Peer Perform → Underperform
Oct-16-24 Initiated Scotiabank Sector Outperform
Aug-16-24 Upgrade Goldman Neutral → Buy
Feb-16-24 Downgrade Goldman Buy → Neutral
Feb-15-24 Initiated Wolfe Research Peer Perform
Dec-08-23 Initiated Wells Fargo Equal Weight
Oct-11-23 Downgrade Oppenheimer Outperform → Perform
Sep-29-23 Initiated Raymond James Outperform
May-05-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-26-23 Initiated SMBC Nikko Neutral
Mar-21-23 Initiated Bernstein Outperform
Jan-18-23 Initiated Canaccord Genuity Buy
Sep-09-22 Resumed Morgan Stanley Equal-Weight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
Jun-27-22 Downgrade Guggenheim Buy → Neutral
Jun-07-22 Initiated William Blair Outperform
Apr-25-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Mar-01-22 Initiated Citigroup Buy
Feb-03-22 Upgrade Guggenheim Neutral → Buy
Jan-03-22 Upgrade Piper Sandler Neutral → Overweight
Nov-22-21 Upgrade Goldman Neutral → Buy
Nov-22-21 Upgrade RBC Capital Mkts Sector Perform → Outperform
Nov-01-21 Upgrade Oppenheimer Perform → Outperform
Oct-04-21 Upgrade UBS Neutral → Buy
Aug-04-21 Downgrade Piper Sandler Overweight → Neutral
Feb-22-21 Downgrade Guggenheim Buy → Neutral
Feb-12-21 Downgrade Citigroup Buy → Neutral
Feb-12-21 Reiterated H.C. Wainwright Buy
Jan-25-21 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-30-20 Resumed Berenberg Hold
Sep-08-20 Initiated Citigroup Buy
Aug-11-20 Downgrade Oppenheimer Outperform → Perform
May-13-20 Initiated RBC Capital Mkts Sector Perform
May-07-20 Downgrade JP Morgan Overweight → Neutral
Apr-24-20 Resumed Evercore ISI Outperform
Mar-19-20 Initiated Berenberg Buy
Dec-19-19 Reiterated Chardan Capital Markets Buy
Nov-20-19 Initiated Oppenheimer Outperform
Nov-13-19 Initiated BofA/Merrill Buy
May-23-19 Resumed Goldman Neutral
Apr-12-19 Initiated Evercore ISI Outperform
Mar-06-19 Upgrade Evercore ISI In-line → Outperform
Mar-05-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-23-19 Initiated UBS Neutral
Oct-01-18 Initiated Cantor Fitzgerald Overweight
Aug-13-18 Reiterated Stifel Buy
Aug-07-18 Upgrade Stifel Hold → Buy
May-04-18 Reiterated Stifel Hold
Mar-28-18 Initiated Evercore ISI In-line
View All

Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News

pulisher
11:06 AM

Truist Securities Raises Price Target for Alnylam Pharmaceuticals (ALNY) by 16.56% | ALNY Stock News - GuruFocus

11:06 AM
pulisher
09:38 AM

Alnylam stock price target raised to $535 from $459 by Truist Securities - Investing.com

09:38 AM
pulisher
03:09 AM

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results - BioSpace

03:09 AM
pulisher
Oct 16, 2025

Alnylam Pharmaceuticals (ALNY): Assessing Valuation Following New Partnerships, Pipeline Progress, and Fresh Financing - Yahoo Finance

Oct 16, 2025
pulisher
Oct 16, 2025

Responsive Playbooks and the ALNY Inflection - news.stocktradersdaily.com

Oct 16, 2025
pulisher
Oct 16, 2025

Is the Options Market Predicting a Spike in Alnylam Pharmaceuticals Stock? - sharewise.com

Oct 16, 2025
pulisher
Oct 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD By Investing.com - Investing.com Nigeria

Oct 15, 2025
pulisher
Oct 15, 2025

Are You Looking for a Top Momentum Pick? Why Alnylam Pharmaceuticals (ALNY) is a Great Choice - Yahoo Finance

Oct 15, 2025
pulisher
Oct 15, 2025

Custom watchlist performance reports with Alnylam Pharmaceuticals Inc.2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com

Oct 15, 2025
pulisher
Oct 15, 2025

Alnylam Pharmaceuticals stock hits all-time high at 484.5 USD - Investing.com India

Oct 15, 2025
pulisher
Oct 15, 2025

What Catalysts Are Shaping the Evolving Narrative for Alnylam Pharmaceuticals? - Yahoo Finance

Oct 15, 2025
pulisher
Oct 14, 2025

Is Alnylam Pharmaceuticals Inc. stock ready for breakoutAnalyst Upgrade & Free High Accuracy Swing Entry Alerts - newser.com

Oct 14, 2025
pulisher
Oct 14, 2025

The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran - simplywall.st

Oct 14, 2025
pulisher
Oct 14, 2025

Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock - Yahoo Finance

Oct 14, 2025
pulisher
Oct 14, 2025

Is Alnylam Pharmaceuticals (ALNY) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Oct 14, 2025
pulisher
Oct 14, 2025

Will Alnylam Pharmaceuticals Inc. stock sustain high P E ratiosJuly 2025 Update & Safe Capital Allocation Plans - newser.com

Oct 14, 2025
pulisher
Oct 13, 2025

Has Alnylam Pharmaceuticals Inc. found a price floorMarket Risk Summary & Verified Swing Trading Watchlist - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

JP Morgan Lowers Price Target for ALNY, Maintains Overweight Rat - GuruFocus

Oct 13, 2025
pulisher
Oct 13, 2025

What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Weekly Stock Report & Fast Moving Trade Plans - newser.com

Oct 13, 2025
pulisher
Oct 13, 2025

Alnylam Pharma Secures $500M Credit Agreement - MSN

Oct 13, 2025
pulisher
Oct 13, 2025

Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 13, 2025
pulisher
Oct 13, 2025

Callan Family Office LLC Raises Stake in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 13, 2025
pulisher
Oct 13, 2025

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Leader with a Robust Pipeline and Strong Buy Ratings - DirectorsTalk Interviews

Oct 13, 2025
pulisher
Oct 13, 2025

What to do if you’re stuck in Alnylam Pharmaceuticals Inc.2025 Technical Overview & High Accuracy Trade Alerts - newser.com

Oct 13, 2025
pulisher
Oct 12, 2025

Sivik Global Healthcare LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 12, 2025
pulisher
Oct 12, 2025

Aberdeen Group plc Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 12, 2025
pulisher
Oct 11, 2025

Alnylam Pharmaceuticals (ALNY): Valuation Snapshot Following New Phase 3 Data and Pipeline Progress - simplywall.st

Oct 11, 2025
pulisher
Oct 11, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 11, 2025
pulisher
Oct 11, 2025

H.C. Wainwright Reaffirms Their Buy Rating on Alnylam Pharma (ALNY) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 10, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growthJuly 2025 Catalysts & High Accuracy Swing Trade Signals - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

ALNY: HC Wainwright & Co. Reiterates Buy Rating with $570 Price Target | ALNY Stock News - GuruFocus

Oct 10, 2025
pulisher
Oct 10, 2025

Is Alnylam Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Trade Ideas & Stock Timing and Entry Methods - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

Using AI based signals to follow Alnylam Pharmaceuticals Inc.Trade Volume Summary & High Conviction Buy Zone Alerts - newser.com

Oct 10, 2025
pulisher
Oct 10, 2025

What drives Alnylam Pharmaceuticals Inc stock priceGlobal Trade Effects & Access Risk Ratings for Every Stock - earlytimes.in

Oct 10, 2025
pulisher
Oct 09, 2025

Alnylam and Regeneron Join Forces in Promising Alzheimer’s Study - TipRanks

Oct 09, 2025
pulisher
Oct 09, 2025

KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 09, 2025
pulisher
Oct 09, 2025

Mirae Asset Global Investments Co. Ltd. Has $1.56 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Oct 09, 2025
pulisher
Oct 08, 2025

Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat

Oct 08, 2025
pulisher
Oct 08, 2025

Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN

Oct 08, 2025
pulisher
Oct 08, 2025

Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com

Oct 08, 2025
pulisher
Oct 07, 2025

RNAi: The Benefits Of Shooting The Messenger - Seeking Alpha

Oct 07, 2025
pulisher
Oct 06, 2025

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga

Oct 06, 2025
pulisher
Oct 06, 2025

Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st

Oct 06, 2025
pulisher
Oct 06, 2025

Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morg - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus

Oct 06, 2025
pulisher
Oct 06, 2025

Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com

Oct 06, 2025
pulisher
Oct 06, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat

Oct 06, 2025
pulisher
Oct 06, 2025

Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener

Oct 06, 2025
pulisher
Oct 06, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com

Oct 06, 2025

Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Greenstreet Yvonne
Chief Executive Officer
Oct 02 '25
Sale
452.05
8,924
4,034,085
65,409
Tanguler Tolga
EVP, Chief Commercial Officer
Oct 02 '25
Sale
452.05
1,405
635,126
27,438
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Oct 02 '25
Sale
452.05
2,441
1,103,451
25,231
Garg Pushkal
EVP Chief R&D
Oct 03 '25
Sale
451.48
3,022
1,364,387
20,221
Garg Pushkal
EVP Chief R&D
Oct 02 '25
Sale
452.05
2,937
1,327,675
23,243
$578.05
price up icon 1.56%
$843.66
price up icon 0.76%
$165.76
price up icon 1.57%
biotechnology ONC
$316.42
price down icon 0.50%
$105.14
price up icon 0.06%
Cap:     |  Volume (24h):